Cargando…

Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom

AIMS: Statins are widely used to prevent cardiovascular events, but little is known about the impact of different risk factors for statin-related myopathy or their relevance to reports of other types of muscle symptom. METHODS AND RESULTS: An observational analysis was undertaken of 171 clinically a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hopewell, Jemma C, Offer, Alison, Haynes, Richard, Bowman, Louise, Li, Jing, Chen, Fang, Bulbulia, Richard, Lathrop, Mark, Baigent, Colin, Landray, Martin J, Collins, Rory, Armitage, Jane, Parish, Sarah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544537/ https://www.ncbi.nlm.nih.gov/pubmed/32702748 http://dx.doi.org/10.1093/eurheartj/ehaa574

Ejemplares similares

Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials
por: Offer, Alison, et al.
Publicado: (2019)

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study
por: Hopewell, Jemma C., et al.
Publicado: (2013)

Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
por: Parish, Sarah, et al.
Publicado: (2018)

The role of lipoprotein (a) in chronic kidney disease
por: Hopewell, Jemma C., et al.
Publicado: (2018)

Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial
por: Parish, Sarah, et al.
Publicado: (2022)

Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)
por: Mihaylova, Borislava, et al.
Publicado: (2016)

Neprilysin inhibition in chronic kidney disease
por: Judge, Parminder, et al.
Publicado: (2015)

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
por: Haynes, Richard, et al.
Publicado: (2013)

Weight loss in a cardiovascular trial population identifies people at future risk of dementia
por: van der Veere, Pieter, et al.
Publicado: (2022)

Investigating modifications to participant information materials to improve recruitment into a large randomized trial
por: Haynes, Richard, et al.
Publicado: (2019)

A key risk indicator approach to central statistical monitoring in multicentre clinical trials: method development in the context of an ongoing large-scale randomized trial
por: Elsa, Valdés-Márquez, et al.
Publicado: (2011)

Central statistical monitoring in multicentre clinical trials: developing statistical approaches for analysing key risk indicators
por: Valdes-Marquez, Elsa, et al.
Publicado: (2013)

Myopathy with Concurrent Tadalafil and Simvastatin
por: Gargante, Maria Pia, et al.
Publicado: (2009)

Improving efficiency of on-site monitoring in multicentre clinical trials by targeting visits
por: Knott, Carol, et al.
Publicado: (2015)

Evidence for the Prevention and Treatment of Stroke in Dialysis Patients
por: Herrington, William, et al.
Publicado: (2015)

Impact of ADCY9 Genotype on Response to Anacetrapib
por: Hopewell, Jemma C., et al.
Publicado: (2019)

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2019)

Long-term post-trial follow-up of participants in randomised trials: lessons learned from the mrc / bhf heart protection study (HPS)
por: Aung, Theingi, et al.
Publicado: (2013)

Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial–Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial
por: Harper, Charlie, et al.
Publicado: (2021)

Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data
por: Harper, Charlie, et al.
Publicado: (2023)

Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology
por: Staplin, Natalie, et al.
Publicado: (2022)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
por: Storey, Benjamin C., et al.
Publicado: (2018)

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy
por: Mangravite, Lara M., et al.
Publicado: (2013)

ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes
por: Bowman, Louise, et al.
Publicado: (2018)

Can vascular mortality be reliably ascertained from the underlying cause of death recorded on a medical death certificate? Evidence from 2800 adjudicated heart protection study (HPS) deaths
por: Herrington, William, et al.
Publicado: (2015)

Post-trial follow-up methodology in large randomized controlled trials: a systematic review protocol
por: Llewellyn-Bennett, Rebecca, et al.
Publicado: (2016)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
por: Zhu, Pengfei, et al.
Publicado: (2020)

Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
por: Parish, Sarah, et al.
Publicado: (2023)

The joint effects of apolipoprotein B, apolipoprotein A(1), LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls†
por: Parish, Sarah, et al.
Publicado: (2009)

Quality by design: using intelligent forms to ensure study protocol compliance and participant safety
por: Dayanandan, Rejive, et al.
Publicado: (2015)

Methodology for UK recruitment into a large-scale international clinical trial
por: Wincott, Elizabeth, et al.
Publicado: (2015)

Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD
por: Morton, Rachael L., et al.
Publicado: (2016)

Recruiting patients cost-effectively by mail
por: Aung, Theingi, et al.
Publicado: (2011)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
por: Baigent, Colin, et al.
Publicado: (2011)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2017)

Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis
por: Mafham, Marion, et al.
Publicado: (2011)

Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP)
por: Haynes, Richard, et al.
Publicado: (2014)

What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
por: Kent, Seamus, et al.
Publicado: (2015)

Impact of Outcome Adjudication in Kidney Disease Trials: Observations From the Study of Heart and Renal Protection
por: Herrington, William G., et al.
Publicado: (2023)

Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke
por: Hopewell, Jemma C, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g0ukk2s5d7hd7u2kd8sse23i5n